

1 Review

2 4-hydroxynonenal in redox homeostasis of stomach 3 in health and diseases

4 Andriy Cherkas¹ and Neven Zarkovic^{2,*}

5 ¹ Department of Internal Medicine #1, Danylo Halystkyi Lviv National Medical University, Lviv, Ukraine;
6 cherkasandriy@yahoo.com

7 ² Laboratory for Oxidative Stress (LabOS), Institute "Rudjer Boskovic", Zagreb, Croatia; zarkovic@irb.hr

8 * Correspondence: Laboratory for Oxidative Stress (LabOS), Institute "Rudjer Boskovic" Bijenička 54, HR-
9 10000 Zagreb, Croatia; zarkovic@irb.hr

10

11 Abstract:

12 The integrity, high functional activity and sufficient regeneration rate of gastric mucosa (GM) in
13 harsh conditions is very challenging pathophysiological demand. The health of gastric epithelium
14 highly depends of efficiency of redox balance maintenance, antioxidant defense and activity of
15 detoxifying systems within the cells as well as robustness of blood supply. Bioactive products of
16 lipid peroxidation, in particular second messengers of free radicals, the bellwether of which is 4-
17 hydroxynonenal (HNE), are important mediators in (patho)physiological adaptive reactions, cells
18 signaling, and are also implicated in pathogenesis of numerous gastric diseases. However, while
19 mechanisms and consequences of HNE and its protein adducts production in response to strong
20 stressors during acute and chronic gastric injury are well studied, many other important issues
21 related to gastric carcinogenesis, tumor growth and progression, the condition of GM after
22 eradication of *Helicobacter pylori*, the relevance of antioxidants for HNE-related redox homeostasis
23 in GM and many other still need extensive studies and new comprehensive approaches. Therefore,
24 in order to address existing issues preclinical studies and clinical intervention trials are required,
25 which should include also determination of HNE preferably by immunohistological and specific
26 HNE-His ELISA analyses.

27 **Keywords:** 4-Hydroxynonenal; lipid peroxidation; redox balance; oxidative stress; stomach; peptic
28 ulcer; gastritis; *Helicobacter pylori*; gastric cancer; non-steroid anti-inflammatory drugs-induced
29 gastropathy

30

31 1. Introduction

32 Gastrointestinal tract serves as a highly specialized interface between environment and
33 organism's internal medium aimed primarily to digest food, absorb nutrients and water. In addition,
34 it is responsible for a wide variety of other important functions including, but not limited to, immune
35 defense, excretion of metabolic waste/detoxification, secretory/regulation, repository for gut bacteria,
36 and physical barrier[1]. The gut it is exposed mechanically and chemically to food/chyme, digestive
37 enzymes, different, often very aggressive pH conditions and numerous bacteria, therefore, high
38 efficiency of protection and regeneration is required for its function. It is particularly important in
39 case of stomach, where extremely aggressive acidic pH often reaching the values of 1-2 is
40 accompanied with the action of proteolytic enzymes [2]. Numerous toxins that may be ingested
41 together with food, as well as some drugs may contribute to the damage of gastric mucosa (GM) and
42 expose it to additional risk. Furthermore, in more than a half of the population worldwide bacterial
43 agent, known as *Helicobacter pylori* (*H. pylori*)[3], persists in GM and causes chronic gastritis, peptic
44 ulcer and is major contributor to gastric adenocarcinoma and MALT-lymphoma [4].

45 The redox balance is a major homeostatic parameter and regulatory factor for the metabolic
46 functions of the organism and gut in particular[5]. Redox imbalance often referred to as “oxidative
47 stress” may be caused either by exposure to excessive power of oxidants, or decreased activity of
48 reducing systems and lack of antioxidants [6]. Certain degree of lipid peroxidation may take place in
49 many cellular processes in physiological conditions, but redox imbalance that is typical for a wide
50 range of diseases very often leads to excessive accumulation of oxidized lipids and their degradation
51 products. Among such products of lipid peroxidation 4-hydroxy-2-nonenal (HNE), is known to be
52 ubiquitous and one of the most studied also considered as “second messenger of free radicals” [7]. It
53 is generated from of omega-6 fatty acids, along with its role in pathogenesis of multiple diseases has
54 been shown to be involved in various signaling pathways. It contributes to the regulation of energy
55 metabolism, detoxification, cell proliferation and differentiation, maintenance of cytoskeleton,
56 metabolic adaptations to redox derangements as well as a number of other functions [8–10].

57 Considering sophisticated functions of mucous membrane and a wide variety of damaging
58 exposures, the maintenance of redox balance in GM is particularly challenging [5]. On one hand, the
59 cells of mucosal epithelium have high rate of proliferation and an exceptional regenerative potential,
60 while on the other hand, gastritis, peptic ulcer and gastric cancer remain among the most common
61 gastrointestinal diseases that cause severe health and overall socio-economic damage [3]. The general
62 progress in understanding the roles of lipid peroxidation and HNE as its end-product in health and
63 disease stimulated respective studies focused on specific diseases of stomach and gastrointestinal
64 tract. Our mini-review is aimed to address the most important issues related to the role of HNE in
65 normal functioning and development of the diseases of stomach.

66 2. Approaches to determine HNE in case of diseases of stomach

67 Along with conventional approach to measure the concentrations of substances of interest in
68 biological liquids like blood (serum, plasma, whole blood), urine, cerebrospinal fluid etc., in case of
69 diseases of stomach, several other options are available. First, stomach is available for endoscopy
70 which is a routine clinical intervention. During endoscopy it is possible to obtain biopsies of mucous
71 membrane from different parts of stomach for further morphological studies. Second, gastric juice
72 can be obtained for chemical analysis. Third, a number of “breath-tests” (determination of
73 metabolites of ingested reagents in exhaled air) are available for gastroenterological diagnostics. And
74 finally, some tests can be performed with the use of feces as a material, for example, to test *H. pylori*
75 bacterial contamination [3]. The researchers have to keep in mind that the blood from stomach flows
76 through portal vein to the liver and many substances, for example xenobiotics, lipid peroxidation
77 products, some hormones and cytokines may be cleaved there and thus, may appear in peripheral
78 blood within normal concentration range despite the clear evidence of toxicity/inflammation etc. [11].


79 HNE and other lipid peroxidation products, such as for example acrolein, malonic dialdehyde
80 and many others can be used as biomarkers of redox imbalance [7]. However, their high reactivity
81 and capacity for interactions with multiple functional groups of macromolecules significantly
82 reduces concentrations of free lipid peroxidation products and their transfer to blood and/or urine
83 from other compartments of the organism. Therefore, the most of the detectable HNE is found to be
84 conjugated with proteins or glutathione. Through a Michael-type reaction of nucleophilic addition
85 HNE binds covalently with cysteine, lysine and histidine residues of proteins [12]. Development of
86 specific antibodies against HNE-histidine adducts facilitated further research and enabled
87 implementation of respective analytical methods [13,14].

88 In this regard, widely used methods of HNE determination in human samples include HNE-
89 immunohistochemistry (qualitative/semiquantitative evaluation) that is used in order to map tissue
90 or intracellular distribution of respective HNE-conjugates in the samples, obtained by the means of
91 gastric biopsy [12]. A variety of HNE-ELISA (quantitative methods) have been proposed that are
92 applicable also for evaluation of the levels of HNE-adducts in biological fluids like blood serum, urine
93 or gastric juice [15]. Other antibody-based methods including immune fluorescence, immune-gold
94 electron microscopy, Western-blotting, immunoblotting etc. that are also often successfully used [16].
95 In turn, free HNE can be accurately determined by high performance liquid chromatography and a

96 number of modifications of mass spectroscopy-based methods [17]. However, due to high reactivity
 97 of free HNE appropriate handling of the samples can be very problematic and its levels in many cases
 98 are very low, therefore the determination of respective conjugates reveals more biologically/clinically
 99 relevant information and may have substantial advantages [12].

100 3. HNE in stomach under physiological conditions

101 In physiological conditions ingested food is exposed to low pH (hydrochloric acid) and
 102 proteolytic enzymes in order to provide degradation of proteins to peptides and amino-acids.
 103 However, a highly-acidic medium facilitates also a variety of chemical reactions between different
 104 food components [1,2]. A modelling of chemical processes taking place during gastric digestion
 105 reveals the possibility of iron- or metmyoglobin-catalyzed generation of substantial amounts of
 106 hydroperoxides and other lipid peroxidation products from components of common diets containing
 107 meat and unsaturated fats at low pH in presence of water-dissolved oxygen. Notably, addition of
 108 food rich on polyphenols dramatically reduces generation of hydroperoxides and may be at least in
 109 part responsible for preventive effects of fruits and vegetables [2].



110

111 **Figure 1.** Schematic presentation of major sources of HNE in gastric mucosa and the ways of its
 112 further transformations. Free HNE is a highly reactive molecule and is capable to react with
 113 numerous targets within the cells interfering with redox-sensitive pathways. Metabolites of HNE are
 114 less important for signaling, however, HNE-protein/peptide adducts could develop on numerous
 115 enzymes, cytokine and receptors so they have important regulatory roles, in particular since HNE-
 116 binding is often reversible. Hence, such aldehydic adducts can represent source of HNE and
 117 secondary oxidative stress, while they can also be used for immunochemical HNE detection in the
 118 cells and tissues as advanced lipoxidation end products (ALEs).
 119

120 However, accumulation of exogenous lipid peroxidation products in GM may be enhanced by
 121 consumption of large amounts of unsaturated fats that may be a part of many "healthy" diets or
 122 popular supplements containing polyunsaturated fatty acids (PUFAs) [18]. Therefore, the products
 123 containing significant quantities of PUFAs should be carefully processed and properly stored in order
 124 to prevent their oxidation and possible toxic impact on GM. Actual levels of HNE in GM are the
 125 function of the rates of their generation/absorption and utilization [19]. The formation of protein
 126 conjugates is proportional to the mean levels of free HNE in the cells, therefore antibody-based
 127 methods of staining and quantitative determination of HNE are considered to be quite accurate and
 128 reliable, especially if HNE-histidine adducts are monitored [12].

129 Certain degree of accumulation of HNE-histidine adducts in mucosa of gastric corpus and
130 antrum was demonstrated in majority of healthy volunteers [20]. Notably, almost all the samples,
131 obtained from asymptomatic apparently healthy subjects regardless of whether the patients have
132 been *H. pylori*-positive or not, have had mild to moderate HNE-immunopositivity in cytoplasm of
133 gastric glandular epithelium, with only a few cases of HNE-negative samples [20]. The reasonable
134 explanation of these findings suggests that HNE plays a role in normal signalling and regulation of
135 cellular functions in GM under physiological conditions and its levels are strictly maintained within
136 reasonable range providing adaptations to adverse factors like metabolic or emotional stress,
137 exogenous toxins that are occasionally ingested with food or latent *H. pylori* infection. The impacts
138 with excessive power may lead to distress and cause GM injury and inflammation that is discussed
139 below.


140 Interestingly, the most of *H. pylori*-positive subjects never experience clinically overt forms of
141 gastritis, peptic ulcer or gastric cancer [21]. This observation lays in line with the findings, that
142 apparently healthy *H. pylori*-positive subjects have no difference in HNE-histidine conjugates in GM
143 compared to controls, despite occasional presence of inflammatory cells in the samples [20]. It is
144 likely, that asymptomatic subjects have sufficient compensatory power to cope with the negative
145 influence of the pathogen and only excessive virulence of certain *H. pylori* strains or reduced due to
146 different reasons resistance of host organism leads to clinically significant manifestations. It is known
147 that, for example, sedentary lifestyle is leading to deleterious metabolic changes that are associated
148 with activation of symapthetic tone (with subsequent parasympathetic impairment) [22]. Genetic
149 defects, psychoemotional stress and a number of other factors may also contribute to autonomic
150 imbalance that may contribute to increased vulnerability of GM [23–25].

151 On the other hand, numerous epidemiological observations associate *H. pylori*-positivity with so
152 called extra-gastric manifestations that include, but are not limited to atherosclerosis, insulin
153 resistance/diabetes type 2, diseases of liver and pancreas etc. [26–30]. Proposed pathogenesis include
154 an initial damage of GM caused by *H. pylori* and its virulence factors, oxidative stress and lipid
155 peroxidation, local inflammation, release of pro-inflammatory cytokines and other bioactive
156 mediators to the blood circulation thus causing systemic effects and metabolic derangements that
157 result in respective extra-gastric disease [4,31–34]. Indeed, in *H. pylori*-positive healthy male subjects
158 with sedentary lifestyle higher levels of fasting insulin and elevated homeostatic model assessment
159 index (HOMA-index) were observed compared to *H. pylori*-negative matches [28]. The other study
160 showed significantly increased heart rate and sympathetic tone in *H. pylori* positive asymptomatic
161 volunteers. However, the levels of water-soluble HNE derivative 1,4-dihydroxynonane mercapturic
162 acid (DHN-MA), iso-PGF₂, pro and anti-inflammatory cytokines, C-reactive protein, and a number
163 of selected hormones were not different between the groups, indicating that either the degree of local
164 mucosal damage is not strong enough to cause marked elevation of studied factors or their
165 mild/moderate elevation is cleaved by the passage of blood through the liver [33].

166 4. The HNE presence in patients with *H. pylori*-associated gastritis and peptic ulcer

167 Despite of its recent decline, the prevalence of *H. pylori* infection it is still extremely high world-
168 wide reaching the rates between 20-40% in Western countries to over 90% in many developing
169 countries [3]. There is a clear evidence that this microorganism is causative factor for chronic gastritis
170 type B and peptic ulcer. However, as it was mentioned above, most of *H. pylori*-positive subjects are
171 clinically healthy and never develop gastritis or ulcer. This suggests that along with *H. pylori* and its
172 virulence factors, conditions of host organism play a crucial role in the results of this complex host-
173 microbe interaction [4,35]. This fits well into the framework of the classical concept of balance of
174 factors of “aggression” and “cytoprotection” in GM. On the cellular level this paradigm is consistent
175 with current understanding of the principles of redox balance maintenance under stress
176 conditions[6]. Namely, GM injury and subsequent inflammation takes place when the capacity of
177 antioxidant mechanisms is not sufficient to protect the cells from the damaging factors and related
178 oxidative stress [5].

179 Peptic ulcer and gastritis are for a long time known to be associated with redox imbalance and
 180 excessive lipid peroxidation [36], as was confirmed in numerous studies and with different study
 181 models [37]. Clinical studies are less abundant and only a few of them are addressing the issue of
 182 oxidative stress and lipid peroxidation in GM. The use of gastric endoscopy enables the obtaining of
 183 the mucosal tissue samples for further histological examination. In the group of *H. pylori*-positive
 184 peptic ulcer patients significantly higher accumulation of HNE-histidine adducts in GM compared
 185 to control group was clearly demonstrated [20]. Notably, in some cases severe immunopositivity of
 186 nuclei and perinuclear spaces along with diffuse accumulation of HNE-histidine conjugates in
 187 cytoplasm of the cells was observed, confirming the evidence of decompensated redox imbalance in
 188 GM of these patients [20,38].



189

190 **Figure 2.** Dose-dependent effects of HNE levels on regulation of cellular functions in gastric
 191 mucosa. Actual concentration of HNE inversely correlates with the redox status of the cell and is a
 192 function of the rate of its generation and utilization. HNE content is regulated by the activities of
 193 alcohol and aldehydes dehydrogenases and of glutathione S-transferases, depending mostly on the
 194 level of reduced glutathione and affinity for the other cellular proteins [39]. The overall
 195 pathophysiological consequences reflect the tissue/cellular redox (un)balance, the type of cells and
 196 the reaction of neighboring cells to the onset of lipid peroxidation and HNE generation in the cells
 197 studied, which often behave as individuals, not as constituents of any tissue, which is relevant for
 198 carcinogenic effects of HNE and for its involvement in host defense against cancer [40–43].

199

200 Pharmacological approach to treat chronic gastritis and peptic ulcer via eradication of *H. pylori*
 201 proved to be very successful from the clinical point of view and provided great improvement of
 202 treatment efficiency and allows to cure these diseases in most of the patients [44]. In addition, there
 203 are reasons to expect that eradication of this microorganism may be useful for prevention and/or
 204 treatment of other diseases, associated with *H. pylori*, including metabolic syndrome, type 2 diabetes,
 205 non-alcoholic fatty liver disease, atherosclerosis and possibly several others [45–47]. However,
 206 precise mechanisms of how the infection leads to systemic pathological effects as well as biochemical
 207 mechanisms that may contribute to metabolic deteriorations in *H. pylori* positive patients need to be
 208 further elucidated.

209 Despite obvious clinical efficiency, there are reports indicating persistence of HNE-histidine
 210 adducts hyper-accumulation in peptic ulcer patients even after successful eradication of *H. pylori* at
 211 least in the period of 4 weeks after completing anti-microbial treatment [38]. This is consistent with
 212 clinical observations that some patients still have symptoms (epigastric pain, nausea, reduced

213 appetite etc.) for several months after treatment [48]. It might be possible that metabolic dysfunction
214 in these patients, as integral part of ulcer disease, contributes to pathogenesis of gastric injury
215 independently to *H. pylori*. Combination of these two factors and additionally other factors is known
216 to increase the risk of ulcerations, like smoking, psycho-emotional stress, unhealthy lifestyle and
217 suboptimal nutrition may be crucial for the outcome of host-microbial interaction [24,49]. Thus, it
218 depends on the power of intrinsic cytoprotective mechanisms (genetics, sufficient blood
219 microcirculation in stomach, effective autonomic regulation) and exogenous factors (*H. pylori*,
220 ingestion of toxins and products of PUFAs peroxidation) and may vary from long-term
221 asymptomatic carrying to chronic gastritis type B with the periods of exacerbation and remission,
222 peptic ulcer of stomach and/or duodenum or tumorous transformations in the form of mucosa-
223 associated lymphoid tissue lymphoma (MALT-lymphoma) or gastric adenocarcinoma.

224 5. HNE in gastric carcinogenesis

225 GM is heavily exposed to different types of exogenous chemical agents and many other reactive
226 species are generated directly in the stomach during process of digestion. Some of them may be toxic
227 and cause the damage to gastric epithelium, and some may also be carcinogenic [2]. Chronic
228 inflammation and oxidative stress caused by *H. pylori* infection are also major contributors to
229 malignant transformation of the cells of GM [31,50]. The idea to eradicate *H. pylori* in all carriers, even
230 asymptomatic, is growing in popularity and there some recently published results of respective trials
231 confirming this reasoning [51]. Moreover, eradication of *H. pylori* seems to be reasonable also in
232 patients with early stages of gastric cancer undergoing endoscopic resection since it decreases the
233 rates of metachronous cancers comparing to control group [52]. In this context, genotoxicity of
234 supraphysiological levels of HNE and other lipid peroxidation products may be important for
235 carcinogenesis as well [53].

236 The role of HNE in malignant transformation and growth is ambiguous. On one hand, HNE can
237 diffuse from the site of generation into the nucleus and bind covalently to the molecule of DNA
238 causing mutations and supporting carcinogenesis, while on the other hand, it is influencing pathways
239 regulating proliferation, differentiation and apoptosis of transformed cells. Depending on the
240 concentration and activity of detoxifying systems of cancer cells the effects of HNE may be toxic to
241 them or can stimulate their growth and enforce resistance to cytostatic drugs [54].

242 While in case of acute and chronic GM injury caused by *H. pylori* and gastrotoxic agents oxidative
243 stress and increased lipid peroxidation is well documented, in case of gastric cancer it is not the case.
244 As it was shown by Ma Y., et al. 2013, serum levels of major lipid peroxidation products such as HNE,
245 malonic dialdehyde, conjugated dienes and 8-iso-prostaglandin F_{2α} all were decreased in cancer
246 patients compared to control group [55]. Hence not statistically significant, also lower levels of HNE
247 were observed in *H. pylori*-positive vs *H. pylori*-negative patients that may support the idea that
248 moderate (or local) activation of lipid peroxidation may stimulate systemic activation of
249 detoxification mechanisms through, for example, Nrf2-dependent mechanisms [54].

250 6. HNE in alcohol and non-steroid anti-inflammatory drugs-induced gastropathy

251 Alcohol and a rapidly growing use of non-steroid anti-inflammatory drugs (NSAIDs) jointly are
252 the second most important cause of gastric injury after *H. pylori* [49]. The evidence from well-
253 established animal models of GM injury suggests two principal mechanisms responsible for tissue
254 damage. The first, direct toxic effect on GM and the second, limitation of gastric microcirculatory
255 blood flow that is essential for proper rate of proliferation, mucus secretion etc., through decreased
256 levels of gastroprotective prostaglandin E₂ with subsequent endothelial dysfunction and autonomic
257 dysregulation that may cause oxidative stress [56,57]. Both mechanisms contribute to the
258 development of severe local oxidative stress, excessive lipid peroxidation and accumulation of its
259 products, including HNE, mostly covalently bounded to proteins [36].

260 Important role of autonomic dysregulation is often ignored in case of diseases of stomach. It is
261 known that increased sympathetic tone limits blood flow in the organs of gastrointestinal tract and

262 caused endothelial dysfunction which is crucial for gastroprotection, therefore autonomic imbalance
263 may significantly potentiate damaging effects of alcohol and NSAIDs [58,59].

264 7. Pharmacological and non-pharmacological approaches to reduce redox imbalance in GM

265 Considering multiple etiologic and pathogenic factors that may interact with each other and
266 contribute to GM damage, there is a number of different approaches used in order to prevent or treat
267 gastric injuries (Table 1).

268 Hence, eradication of *H. pylori* with a complex of two antibiotics and proton pump inhibitors is
269 proved to be effective in most of the cases of *H. pylori* positive gastritis and peptic ulcer [44]. However,
270 in some of these patients elimination of the microbial factor is not sufficient and symptoms as well as
271 redox imbalance may persist long after completion of the treatment [38,48]. Moreover, eradication of
272 *H. pylori* does not reduce significantly risk of gastric cancer at least within a few years after eradication
273 and statistical difference becomes significant only after 8-10 years [60]. Therefore, other approaches
274 are also needed in order to overcome these limitations and to address other aspects of GM injury
275 pathogenesis.

276 **Table 1.** Selected pharmacological and non-pharmacological interventions and their effects on HNE
277 production/utilization in gastric mucosa.

Intervention	Target process/ pharmacological effect	References
Proton pump inhibitors, H ₂ histamine receptor inhibitors	Reduction of acidity, decreased proteolytic activity of gastric juice/ decreased gastric injury (production of HNE)	[44,49]
Antibiotics	<i>H. pylori</i> eradication/ decreased gastric injury (production of HNE)	[44,49]
NO,CO, H ₂ S-releasing NSAIDs	Release of CO, NO and/or H ₂ S modulates redox signaling, improves endothelial function and improves microcirculation/ reduced production and improved utilization of HNE	[57,58]
Antioxidants/polyphenols present in food	Reduced lipid peroxidation of PUFAs in stomach/ reduced absorption of exogenous HNE	[2,61]
Phytochemical and phytotoxins with moderate prooxidant action	Nrf-2 activators induce expression of antioxidant genes and increase detoxification of HNE	[62,63]
Interval hypoxic training	Improvement of autonomic control of microcirculation and function of internal organs	[64,65]
Exercise, intermittent fasting, caloric restriction	Activation of autophagy, reduction of systemic inflammatory response, improvement of protein quality control and autonomic regulation	[66]
Ulcer-healing drugs (Actovegin, Solcoseryl etc.)	Mechanism unknown, suggested influence on microcirculation and/or endothelial function	[67,68]

278 Since substantial amounts of gastrototoxic substances may be ingested with food or generated
279 during digestion, the idea to use drugs, supplements or certain types of food able to neutralize toxins
280 or reduce the rate of lipid oxidation was actively explored. Indeed, subjects consuming more fruits
281 and vegetables show lower incidence of gastric diseases, especially gastric cancer [69]. Studies show
282 also that polyphenols reduce formation of hydroperoxides in stomach and *in vitro* models of gastric
283 digestion [2,61]. Use of pre- and pro-biotics [70] as well as a number of plant derived traditional
284 medicines or extracts was also shown to be protective against gastric and intestinal mucosal damage
285 and may improve redox balance in mucous membranes in different parts of gastrointestinal tract [63].
286 Exact mechanisms of their effects are often not clear, but at least some of them may act via hormetic
287

288 effect, when moderate prooxidant action is leading to activation of defense mechanisms (for example
289 by stimulation of Nrf-2 transcription factor) [54]. Alternatively, they may contribute to increased
290 mucosal microcirculation through improvement of endothelial function or parasympathetic tone as
291 it is in case of Actvegin, which is used as antiulcer drug for several decades [68]. Among non-
292 pharmacological interventions that showed some efficiency in case of peptic ulcer disease is also
293 interval hypoxic training [64]. Exact gastroprotective mechanisms in this case are not clear as well,
294 but it is likely that the mechanism includes improvements of autonomic balance and enhanced
295 microcirculation [65].

296 Therapeutic use of NSAIDs is overwhelming and in order to reduce their gastrotoxicity a wide
297 range of new formulations are introduced or are under development [71]. For example, a number of
298 nitric oxide (NO), carbon monoxide (CO) or hydrogen sulfide (H₂S) releasing derivatives of
299 acetylsalicylic acid and other NSAIDs were shown to be pharmacologically as effective as traditional
300 drugs, but have preventive effects against NSAID-induced gastrotoxicity via improvement of
301 endothelial function, anti-inflammatory and cytoprotective effects [57,58]. Protective mechanisms of
302 action of these drugs are closely related to HNE signaling pathways and maintenance of redox
303 balance in GM.

304 8. Conclusions

305 The integrity, high functional activity and sufficient regeneration rate of GM in harsh conditions
306 is very challenging. The health of gastric epithelium highly depends of efficiency of redox balance
307 maintenance, antioxidant defense and activity of detoxifying systems within the cells as well as
308 robustness of blood supply. The products of lipid peroxidation, in particular of HNE and its
309 protein/histidine adducts, are important mediators in physiological adaptive reactions, cells
310 signaling, and are also implicated in pathogenesis of numerous gastric diseases. Hence, while the
311 mechanisms and consequences of HNE generation in response to strong stressors during acute and
312 chronic gastric injury are well studied, many other important issues related to gastric carcinogenesis,
313 tumor growth and progression, the condition of GM after eradication of *H. pylori*, and many others
314 still need extensive studies and new comprehensive approaches.
315

316 **Author Contributions:** Both authors contributed to conceptualization, original draft preparation, review &
317 editing and preparation of the figures.

318 **Funding:** This work was supported by COST Actions B35 “LPO-lipid peroxidation associated disorders”,
319 CM1001 “Chemistry of non-enzymatic protein modification – modulation of protein structure and function”,
320 “BM1203 “EU-ROS” “New concepts and views in redox biology and oxidative stress research”, CA16112
321 “Personalized Nutrition in aging society: redox control of major age-related diseases”, A.C. was supported by
322 the Georg Forster (HERMES) Scholarship from Alexander Von Humboldt Foundation (Bonn, Germany).

323 **Acknowledgments:** The authors are grateful to all the colleagues and collaborators that contributed to the
324 research that has been done at the Department of Internal Medicine #1 of Danylo Halytskyi Lviv National
325 Medical University (Lviv, Ukraine), Rudjer Boskovic Institute and School of Medicine of University of Zagreb
326 (Zagreb, Croatia).

327 **Conflicts of Interest:** The authors declare no conflict of interest.

328

329 References

- 330 1. Sherwood, L. Human Physiology: From Cells to Systems. *Hum. Physiol.* **2010**, doi:9781111577438.
- 331 2. Kanner, J.; Lapidot, T. The stomach as a bioreactor: Dietary lipid peroxidation in the gastric fluid and
332 the effects of plant-derived antioxidants. *Free Radic. Biol. Med.* **2001**, doi:10.1016/S0891-5849(01)00718-3.
- 333 3. Mentis, A.; Lehours, P.; Mégraud, F. Epidemiology and Diagnosis of Helicobacter pylori infection.
334 *Helicobacter* **2015**, *20*, 1–7, doi:10.1111/hel.12250.
- 335 4. Sgouras, D. N.; Trang, T. T. H.; Yamaoka, Y. Pathogenesis of Helicobacter pylori Infection. *Helicobacter*

- 336 2015, 20 Suppl 1, 8–16, doi:10.1111/hel.12251.
- 337 5. Pérez, S.; Taléns-Visconti, R.; Rius-Pérez, S.; Finamor, I.; Sastre, J. Redox signaling in the gastrointestinal
338 tract. *Free Radic. Biol. Med.* 2017.
- 339 6. Sies, H.; Berndt, C.; Jones, D. P. Oxidative Stress. *Annu. Rev. Biochem.* 2017, doi:10.1146/annurev-
340 biochem-061516-045037.
- 341 7. Zarkovic, N. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. In *Molecular*
342 *Aspects of Medicine*; 2003.
- 343 8. Neven Žarković, Ana Čipak Gasparović, Marina Cindrić, Georg Waeg, Suzana Borović Šunjić, Lidija
344 Mrakovčić, Morana Jaganjac, Danijela Kolenc, Luka Andrišić, Snježana Gverić Ahmetašević, Ana
345 Katušić, Andriy Cherkas, Gordana Jurić Sekhar, Renate Wildburger, K. Ž. 4-Hydroxynonenal-protein
346 adducts as biomarkers of oxidative stress, lipid peroxidation and oxidative homeostasis. In *Free Radicals*
347 *Health and Lifestyle*; Rome, 2009; pp. 37–44.
- 348 9. Žarković, N.; Žarković, K.; Schaur, R. J.; Štolc, S.; Schlag, G.; Redl, H.; Waeg, G.; Borović, S.; Lončarić, I.;
349 Jurić, G.; Hlavka, V. 4-Hydroxynonenal as a second messenger of free radicals and growth modifying
350 factor. In *Life Sciences*; 1999.
- 351 10. Schaur, R.; Siems, W.; Bresgen, N.; Eckl, P. 4-Hydroxy-nonenal—A Bioactive Lipid Peroxidation
352 Product. *Biomolecules* 2015, 5, 2247–2337, doi:10.3390/biom5042247.
- 353 11. Kirpich, I. A.; Marsano, L. S.; McClain, C. J. Gut-Liver Axis, Nutrition, and Non Alcoholic Fatty Liver
354 Disease. *Clin. Biochem.* 2015, 48, 923–30, doi:10.1016/j.clinbiochem.2015.06.023.
- 355 12. Zarkovic, K.; Jakovcevic, A.; Zarkovic, N. Contribution of the HNE-immunohistochemistry to modern
356 pathological concepts of major human diseases. *Free Radic. Biol. Med.* 2017.
- 357 13. Toyokuni, S.; Miyake, N.; Hiai, H.; Hagiwara, M.; Kawakishi, S.; Osawa, T.; Uchida, K. The monoclonal
358 antibody specific for the 4-hydroxy-2-nonenal histidine adduct. *FEBS Lett.* 1995, doi:10.1016/0014-
359 5793(95)00033-6.
- 360 14. Waeg, G.; Dimsity, G.; Esterbauer, H. Monoclonal antibodies for detection of 4-hydroxynonenal
361 modified proteins. *Free Radic. Res.* 1996, doi:10.3109/10715769609149920.
- 362 15. Weber, D.; Milkovic, L.; Bennett, S. J.; Griffiths, H. R.; Zarkovic, N.; Grune, T. Measurement of HNE-
363 protein adducts in human plasma and serum by ELISA-Comparison of two primary antibodies. *Redox*
364 *Biol.* 2013, 1, 226–33, doi:10.1016/j.redox.2013.01.012.
- 365 16. Sousa, B. C.; Pitt, A. R.; Spickett, C. M. Chemistry and analysis of HNE and other prominent carbonyl-
366 containing lipid oxidation compounds. *Free Radic. Biol. Med.* 2017.
- 367 17. Spickett, C. M.; Wiswedel, I.; Siems, W.; Zarkovic, K.; Zarkovic, N. Advances in methods for the
368 determination of biologically relevant lipid peroxidation products. *Free Radic. Res.* 2010.
- 369 18. Tirosh, O.; Shpaizer, A.; Kanner, J. Lipid Peroxidation in a Stomach Medium Is Affected by Dietary Oils
370 (Olive/Fish) and Antioxidants: The Mediterranean versus Western Diet. *J. Agric. Food Chem.* 2015,
371 doi:10.1021/acs.jafc.5b02149.
- 372 19. Negre-Salvayre, A.; Auge, N.; Ayala, V.; Basaga, H.; Boada, J.; Brenke, R.; Chapple, S.; Cohen, G.; Feher,
373 J.; Grune, T.; Lengyel, G.; Mann, G. E.; Pamplona, R.; Poli, G.; Portero-Otin, M.; Riahi, Y.; Salvayre, R.;
374 Sasson, S.; Serrano, J.; Shamni, O.; Siems, W.; Siow, R. C. M.; Wiswedel, I.; Zarkovic, K.; Zarkovic, N.
375 Pathological aspects of lipid peroxidation. *Free Radic. Res.* 2010.
- 376 20. Yelisyyeva, O.; Cherkas, A.; Zarkovic, K.; Semen, K.; Kaminskyy, D.; Waeg, G.; Zarkovic, N. The
377 distribution of 4-hydroxynonenal-modified proteins in gastric mucosa of duodenal peptic ulcer patients.
378 *Free Radic. Res.* 2008, 42, 205–211.

- 379 21. Cid, T. P.; Fernández, M. C.; Benito Martínez, S.; Jones, N. L. Pathogenesis of *Helicobacter pylori*
380 infection. *Helicobacter* **2013**, *18 Suppl 1*, 12–7, doi:10.1111/hel.12076.
- 381 22. Cherkas, A.; Abrahamovych, O.; Golota, S.; Nersesyan, A.; Pichler, C.; Serhiyenko, V.; Knasmüller, S.;
382 Zarkovic, N.; Eckl, P. The correlations of glycosylated hemoglobin and carbohydrate metabolism parameters
383 with heart rate variability in apparently healthy sedentary young male subjects. *Redox Biol.* **2015**, *5*,
384 doi:10.1016/j.redox.2015.05.007.
- 385 23. Cherkas, A.; Zhuraev, R. A marked decrease in heart rate variability in marfan syndrome patients with
386 confirmed FBN1 mutations. *Cardiol. J.* **2016**, *23*, doi:10.5603/CJ.a2015.0076.
- 387 24. Levenstein, S.; Rosenstock, S.; Jacobsen, R. K.; Jorgensen, T. Psychological stress increases risk for peptic
388 ulcer, regardless of *Helicobacter pylori* infection or use of nonsteroidal anti-inflammatory drugs. *Clin.*
389 *Gastroenterol. Hepatol.* **2015**, doi:10.1016/j.cgh.2014.07.052.
- 390 25. Haensel, A.; Mills, P. J.; Nelesen, R. A.; Ziegler, M. G.; Dimsdale, J. E. The relationship between heart
391 rate variability and inflammatory markers in cardiovascular diseases. *Psychoneuroendocrinology* **2008**.
- 392 26. Polyzos, S. A.; Kountouras, J. Novel Advances in the Association Between *Helicobacter pylori* Infection,
393 Metabolic Syndrome, and Related Morbidity. *Helicobacter* **2015**, *20*, 405–409, doi:10.1111/hel.12228.
- 394 27. Chen, L.-W.; Chien, C.-Y.; Yang, K.-J.; Kuo, S.-F.; Chen, C.-H.; Chien, R.-N. *Helicobacter pylori* Infection
395 Increases Insulin Resistance and Metabolic Syndrome in Residents Younger than 50 Years Old: A
396 Community-Based Study. *PLoS One* **2015**, *10*, e0128671, doi:10.1371/journal.pone.0128671.
- 397 28. Cherkas, A.; Eckl, P.; Guéraud, F.; Abrahamovych, O.; Serhiyenko, V.; Yatskevych, O.; Pliatsko, M.;
398 Golota, S. *Helicobacter pylori* in sedentary men is linked to higher heart rate, sympathetic activity, and
399 insulin resistance but not inflammation or oxidative stress. *Croat. Med. J.* **2016**, *57*,
400 doi:10.3325/cmj.2016.57.141.
- 401 29. Cardaropoli, S.; Rolfo, A.; Todros, T. *Helicobacter pylori* and pregnancy-related disorders. *World J.*
402 *Gastroenterol.* **2014**, *20*, 654–64, doi:10.3748/wjg.v20.i3.654.
- 403 30. Franceschi, F.; Gasbarrini, A.; Polyzos, S. A.; Kountouras, J. Extragastric Diseases and *Helicobacter*
404 *pylori*. *Helicobacter* **2015**, *20 Suppl 1*, 40–6, doi:10.1111/hel.12256.
- 405 31. Hardbower, D. M.; de Sablet, T.; Chaturvedi, R.; Wilson, K. T. Chronic inflammation and oxidative
406 stress: the smoking gun for *Helicobacter pylori*-induced gastric cancer? *Gut Microbes* **4**, 475–81,
407 doi:10.4161/gmic.25583.
- 408 32. Handa, O.; Naito, Y.; Yoshikawa, T. *Helicobacter pylori*: a ROS-inducing bacterial species in the stomach.
409 *Inflamm. Res.* **2010**, *59*, 997–1003, doi:10.1007/s00011-010-0245-x.
- 410 33. Cherkas, A.; Golota, S.; Guéraud, F.; Abrahamovych, O.; Pichler, C.; Nersesyan, A.; Krupak, V.;
411 Bugiichyk, V.; Yatskevych, O.; Pliatsko, M.; Eckl, P.; Knasmüller, S. A *Helicobacter pylori*-associated
412 insulin resistance in asymptomatic sedentary young men does not correlate with inflammatory markers
413 and urine levels of 8-iso-PGF₂ α or 1,4-dihydroxynonane mercapturic acid. *Arch. Physiol.*
414 *Biochem.* **2017**, doi:10.1080/13813455.2017.1396346.
- 415 34. Cherkas, A.; Abrahamovych, O.; Golota, S.; Nersesyan, A.; Pichler, C.; Serhiyenko, V.; Knasmüller, S.;
416 Zarkovic, N.; Eckl, P. The correlations of glycosylated hemoglobin and carbohydrate metabolism parameters
417 with heart rate variability in apparently healthy sedentary young male subjects. *Redox Biol.* **2015**, *5*, 301–
418 307, doi:10.1016/j.redox.2015.05.007.
- 419 35. Yeniova, A. O.; Uzman, M.; Kefeli, A.; Basyigit, S.; Ata, N.; Dal, K.; Guresci, S.; Nazligul, Y. Serum 8
420 Hydroxydeoxyguanosine and Cytotoxin Associated Gene A as Markers for *Helicobacter pylori*
421 Infection. *Asian Pac. J. Cancer Prev.* **2015**, *16*, 5199–203,

- 422 doi:DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5199.
- 423 36. Bhattacharyya, A.; Chattopadhyay, R.; Mitra, S.; Crowe, S. E. Oxidative Stress: An Essential Factor in the
424 Pathogenesis of Gastrointestinal Mucosal Diseases. *Physiol. Rev.* **2014**, doi:10.1152/physrev.00040.2012.
- 425 37. Kwiecien, S.; Jasnos, K.; Magierowski, M.; Sliwowski, Z.; Pajdo, R.; Brzozowski, B.; Mach, T.; Wojcik, D.;
426 Brzozowski, T. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis
427 of gastric mucosal lesions and mechanism of protection against oxidative stress - induced gastric injury.
428 *J Physiol Pharmacol* **2014**.
- 429 38. Cherkas, A.; Yelisseyeva, O.; Semen, K.; Zarković, K.; Kaminsky, D.; Gasparović, A. C.; Jaganjac, M.;
430 Lutsyk, A.; Waeg, G.; Zarkovic, N. Persistent accumulation of 4-hydroxynonenal-protein adducts in
431 gastric mucosa after *Helicobacter pylori* eradication. *Coll. Antropol.* **2009**, *33*, 815–821.
- 432 39. Awasthi, Y. C.; Ramana, K. V.; Chaudhary, P.; Srivastava, S. K.; Awasthi, S. Regulatory roles of
433 glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity. *Free Radic.*
434 *Biol. Med.* **2017**.
- 435 40. Jaganjac, M.; Cacev, T.; Cipak, A.; Kapitanović, S.; Gall Troselj, K.; Zarković, N. Even stressed cells are
436 individuals: second messengers of free radicals in pathophysiology of cancer. *Croat. Med. J.* **2012**,
437 doi:10.3325/cmj.2012.53.304.
- 438 41. Bauer, G.; Zarkovic, N. Revealing mechanisms of selective, concentration-dependent potentials of 4-
439 hydroxy-2-nonenal to induce apoptosis in cancer cells through inactivation of membrane-associated
440 catalase. *Free Radic. Biol. Med.* **2015**, doi:10.1016/j.freeradbiomed.2015.01.010.
- 441 42. Zhong, H.; Xiao, M.; Zarkovic, K.; Zhu, M.; Sa, R.; Lu, J.; Tao, Y.; Chen, Q.; Xia, L.; Cheng, S.; Waeg, G.;
442 Zarkovic, N.; Yin, H. Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in
443 hepatocellular carcinoma: A novel link between oxidative stress and cancer. *Free Radic. Biol. Med.* **2017**,
444 doi:10.1016/j.freeradbiomed.2016.10.494.
- 445 43. Živković, N. P.; Petrovečki, M.; Lončarić, Č. T.; Nikolić, I.; Waeg, G.; Jaganjac, M.; Žarković, K.; Žarković,
446 N. Positron emission tomography-computed tomography and 4-hydroxynonenal-histidine
447 immunohistochemistry reveal differential onset of lipid peroxidation in primary lung cancer and in
448 pulmonary metastasis of remote malignancies. *Redox Biol.* **2017**, doi:10.1016/j.redox.2017.01.005.
- 449 44. Zagari, R. M.; Rabitti, S.; Eusebi, L. H.; Bazzoli, F. Treatment of *Helicobacter pylori* infection: A clinical
450 practice update. *Eur. J. Clin. Invest.* **2018**.
- 451 45. Buzás, G. M.; Gastroenterologist, C. Metabolic consequences of *Helicobacter pylori* infection and
452 eradication. *World J Gastroenterol Buzás GM World J Gastroenterol* **2014**, doi:10.3748/wjg.v20.i18.5226.
- 453 46. Dogan, Z.; Sarikaya, M.; Ergul, B.; Filik, L. The effect of *Helicobacter pylori* eradication on insulin
454 resistance and HbA1c level in people with normal glucose levels: a prospective study. *Biomed. Pap. Med.*
455 *Fac. Univ. Palacký, Olomouc, Czechoslov.* **2015**, *159*, 242–5, doi:10.5507/bp.2014.036.
- 456 47. Longo-Mbenza, B.; Nkondi Nsenga, J.; Vangu Ngoma, D. Prevention of the metabolic syndrome insulin
457 resistance and the atherosclerotic diseases in Africans infected by *Helicobacter pylori* infection and
458 treated by antibiotics. *Int. J. Cardiol.* **2007**.
- 459 48. Kumar, D.; Anjan, D.; Dattagupta, S.; Ahuja, V.; Mathur, M.; P, S. M. Pre and post eradication gastric
460 inflammation in *Helicobacter pylori*-associated duodenal ulcer. *Indian J. Gastroenterol.* **2002**.
- 461 49. Lanas, A.; Chan, F. K. L. Peptic ulcer disease. *Lancet* **2017**.
- 462 50. Hardbower, D. M.; Peek, R. M.; Wilson, K. T. At the Bench: *Helicobacter pylori*, dysregulated host
463 responses, DNA damage, and gastric cancer. *J. Leukoc. Biol.* **2014**, *96*, 201–12, doi:10.1189/jlb.4BT0214-
464 099R.

- 465 51. Bae, S. E.; Choi, K. D.; Choe, J.; Kim, S. O.; Na, H. K.; Choi, J. Y.; Ahn, J. Y.; Jung, K. W.; Lee, J.; Kim, D.
466 H.; Chang, H.-S.; Song, H. J.; Lee, G. H.; Jung, H.-Y. The effect of eradication of *Helicobacter pylori* on
467 gastric cancer prevention in healthy asymptomatic populations. *Helicobacter* **2018**, doi:10.1111/hel.12464.
- 468 52. Choi, I. J.; Kook, M.-C.; Kim, Y.-I.; Cho, S.-J.; Lee, J. Y.; Kim, C. G.; Park, B.; Nam, B.-H. *Helicobacter pylori*
469 Therapy for the Prevention of Metachronous Gastric Cancer. *N. Engl. J. Med.* **2018**,
470 doi:10.1056/NEJMoa1708423.
- 471 53. Eckl, P. M. Genotoxicity of HNE. In *Molecular Aspects of Medicine*; 2003.
- 472 54. Gasparovic, A. C.; Milkovic, L.; Sunjic, S. B.; Zarkovic, N. Cancer growth regulation by 4-
473 hydroxynonenal. *Free Radic. Biol. Med.* **2017**.
- 474 55. Ma, Y.; Zhang, L.; Rong, S.; Qu, H.; Zhang, Y.; Chang, D.; Pan, H.; Wang, W. Relation between gastric
475 cancer and protein oxidation, DNA damage, and lipid peroxidation. *Oxid. Med. Cell. Longev.* **2013**,
476 doi:10.1155/2013/543760.
- 477 56. Kwiecień, S.; Brzozowski, T.; Konturek, S. J. Effects of reactive oxygen species action on gastric mucosa
478 in various models of mucosal injury. *J. Physiol. Pharmacol.* **2002**.
- 479 57. Wallace, John, Irena Pshyk-titko, Marcelo N. Muscara, Nazar Bula, Yaroslav Pavlovsky, Elene Gavruluk,
480 and O. Z. Influence of hydrogen sulphide-releasing Aspirin on mucosal integrity of esophageal and
481 gastric mucosa. *Proc. Shevchenko Sci. Soc.* **2015**, *43*, 63–74.
- 482 58. Kwiecien, S.; Magierowska, K.; Magierowski, M.; Surmiak, M.; Hubalewska-Mazgaj, M.; Pajdo, R.;
483 Sliwowski, Z.; Chmura, A.; Wojcik, D.; Brzozowski, T. Role of sensory afferent nerves, lipid peroxidation
484 and antioxidative enzymes in the carbon monoxide-induced gastroprotection against stress
485 ulcerogenesis. *J. Physiol. Pharmacol.* **2016**.
- 486 59. Abrahamovych, O.; Cherkas, A.; Abrahamovych, U.; Abrahamovych, M.; Serhiyenko, V. *Heart rate*
487 *variability: physiological bases, clinical importance and peculiarities in patients with peptic ulcer and after*
488 *resection of stomach*; Abrahamovych, O., Ed.; Danylo Halytskyi Lviv National Medical University: Lviv,
489 2014; ISBN 978 966 7175-55-9.
- 490 60. O'Connor, A.; O'Morain, C. A.; Ford, A. C. Population screening and treatment of *Helicobacter pylori*
491 infection. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, doi:10.1038/nrgastro.2016.195.
- 492 61. Kim, H.-G.; Bae, J.-H.; Jastrzebski, Z.; Cherkas, A.; Heo, B.-G.; Gorinstein, S.; Ku, Y.-G. Binding,
493 Antioxidant and Anti-proliferative Properties of Bioactive Compounds of Sweet Paprika (*Capsicum*
494 *annuum* L.). *Plant Foods Hum. Nutr.* **2016**, *71*, doi:10.1007/s11130-016-0550-9.
- 495 62. Lushchak, V. I. Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions. *J.*
496 *Amino Acids* **2012**, doi:10.1155/2012/736837.
- 497 63. Cherkas, A.; Zarkovic, K.; Cipak Gasparovic, A.; Jaganjac, M.; Milkovic, L.; Abrahamovych, O.;
498 Yatskevych, O.; Waeg, G.; Yelisyeyeva, O.; Zarkovic, N. Amaranth oil reduces accumulation of 4-
499 hydroxynonenal-histidine adducts in gastric mucosa and improves heart rate variability in duodenal
500 peptic ulcer patients undergoing *Helicobacter pylori* eradication. *Free Radic. Res.* **2018**,
501 doi:10.1080/10715762.2017.1418981.
- 502 64. Semen, K. O.; Yelisyeyeva, O. P.; Kaminsky, D. V.; Cherkas, A. P.; Zarkovic, K.; Lutsyk, O.; Cipak, A.;
503 Jaganjac, M.; Zarkovic, N. Interval hypoxic training in complex treatment of *Helicobacter pylori*-
504 associated peptic ulcer disease. *Acta Biochim. Pol.* **2010**, *57*, 199–208.
- 505 65. Ielisieieva, O. P.; Semen, K. O.; Cherkas, A. P.; Kamins'ky, D. V.; Kurkevych, A. K. Specific mechanisms
506 of individually adjusted interval hypoxic hypercapnic effects on heart rate variability in athletes.
507 *Fiziolohichmy? zhurnal (Kiev, Ukr. 1994)* **2007**, *53*.

- 508 66. Cherkas, A.; Golota, S. An intermittent exhaustion of the pool of glycogen in the human organism as a
509 simple universal health promoting mechanism. *Med. Hypotheses* **2014**, *82*, 387–389,
510 doi:10.1016/j.mehy.2014.01.009.
- 511 67. Gulevsky, A. K.; Abakumova, Y. S.; Moiseyeva, N. N.; Ivanov, Y. G. Influence of Cord Blood Fraction
512 (below 5 kDa) on Reparative Processes during Subchronic Ulcerative Gastropathy. *Ulcers* **2011**, *2011*, 1–
513 9, doi:10.1155/2011/214124.
- 514 68. Stelmakh, A.; Abrahamovych, O.; Cherkas, A. Highly purified calf hemodialysate (Actovegin®) may
515 improve endothelial function by activation of proteasomes: A hypothesis explaining the possible
516 mechanisms of action. *Med. Hypotheses* **2016**, *95*, doi:10.1016/j.mehy.2016.09.008.
- 517 69. Wang, T.; Cai, H.; Sasazuki, S.; Tsugane, S.; Zheng, W.; Cho, E. R.; Jee, S. H.; Michel, A.; Pawlita, M.;
518 Xiang, Y. B.; Gao, Y. T.; Shu, X. O.; You, W. C.; Epplein, M. Fruit and vegetable consumption,
519 Helicobacter pylori antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China,
520 Japan, and Korea. *Int. J. Cancer* **2017**, doi:10.1002/ijc.30477.
- 521 70. Shafaghi, A.; Pourkazemi, A.; Khosravani, M.; Fakhrie Asl, S.; Amir Maafi, A.; Atrkar Roshan, Z.;
522 Abaspour Rahimabad, J. The Effect of Probiotic Plus Prebiotic Supplementation on the Tolerance and
523 Efficacy of Helicobacter Pylori Eradication Quadruple Therapy: a Randomized Prospective Double
524 Blind Controlled Trial. *Middle East J. Dig. Dis.* **2016**, doi:10.15171/mejdd.2016.30.
- 525 71. Gargallo, C. J.; Sostres, C.; Lanas, A. Prevention and Treatment of NSAID Gastropathy. *Curr. Treat.*
526 *Options Gastroenterol.* **2014**, doi:10.1007/s11938-014-0029-4.

527